One problem many investors have is finding companies that are worthy of further research.

Typically, investors will look straight to the big-name companies such as the major banks or the miners, together with Telstra and even Woolworths.

Others tend to look for shares which have rallied strongly based on the expectation they will continue to rise, while some look for those which could be near to bottoming out after a prolonged decline.

There is no right or wrong answer, and every investor has their own approach. However, one of the best ways is to look for companies that have been recommended by stockbrokers and other research houses.

They won’t all be winners, but they can certainly be a source of new ideas for your research.

  1. Aconex Limited (ASX: ACX) has received plenty of attention lately thanks to its incredible share price performance over the last 12 months or so. However, Deutsche Bank still rates it a buy, setting a price target of $7.85 that is 17.5% above today’s price of $6.68. The shares aren’t cheap, per se, but they are worthy of a closer look.
  2. EVOLUTION FPO (ASX: EVN) is also on the radar of financial services group UBS, which has set a price target of $1.98. The gold miner’s share price is already sitting at $1.89, but could have more room to run if the gold price does continue to rise. However, investors should be aware that the shares could also fall from their current level if gold prices do retreat as the level of uncertainty facing the global economy diminishes.
  3. oOh!Media Ltd (ASX: OML) is one of Australia’s leading out-of-home advertising businesses, allowing its customers to advertise their goods and services on the company’s various billboards and static or digital signs. In a fast-growing market, Credit Suisse has set a price target of $4.95, up from its current level of $4.66.
  4. Notably, Credit Suisse is also bullish on oOh!Media’s rival, APN Outdoor Group Ltd (ASX: APO). Although it has already generated huge gains for shareholders in recent times to trade at $6.66 a share, Credit Suisse set a price target of $7.05 earlier this month.

Could these just released franked dividend picks turn $15,000 into over $30,000?

When renowned dividend investing pros like Andrew Page issue buy alerts, it pays to listen. Because investors who followed Andrew's recommendation of Australian Pharmaceuticals in early 2015 could've doubled their money in just over a year, turning $15,000 into over $30,000 by the time he recommended they sell and lock in their profits. Chances are you won't want to miss uncovering the names of Andrew's newest share recommendation and short list of 3 dividend Best Buys Now Shares.
So click here to learn more about these potentially life-changing shares.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.